Does the first dose of Wegovy actually do anything?

The myth: if the first injection doesn't shrink the number on the scales, it isn't working

This is one of the most common misunderstandings our prescribers hear. People expect the first pen to behave like the clinical-trial headline (roughly 15% average weight reduction) and when the scales barely move in week one, they conclude the medicine has failed them. It hasn't. The 0.25 mg dose exists for one reason: to let your digestive system adjust before the semaglutide concentration builds to a level that drives meaningful appetite reduction. Jumping straight to a higher dose would produce more nausea for most people, which is why the schedule is paced the way it is.

The dose schedule typically runs in roughly four-week steps, moving from 0.25 mg upward through 0.5 mg, 1.0 mg and 1.7 mg before reaching 2.4 mg maintenance. Weight loss tends to accelerate as the dose rises. Expecting the first step to deliver the final result is a bit like expecting the first rung of a ladder to put you at the top. The pharmacology is working; the timeline simply hasn't caught up yet.

It is also worth knowing that semaglutide takes several weeks to reach a steady concentration in the body. That accumulation is part of why the medicine's effect deepens over time rather than arriving all at once. Patience at this stage is genuinely part of the treatment, not a sign that something has gone wrong.

What you might actually feel after the first injection

Some people notice nothing at all after 0.25 mg. Others describe a mild reduction in hunger within the first few days, a subtle shift in how quickly they feel full, or a slight drop in enthusiasm for snacking. These early signals are real (the GLP-1 receptor activity slows gastric emptying and affects appetite signalling) but they are often modest at the starting dose.

The side effects most likely to appear in the first week are gastrointestinal: nausea, burping, loose stools or constipation, and occasionally fatigue or mild headache. For most people these are manageable and settle as the body adjusts. They can feel alarming if you weren't expecting them, but the NHS medicines page for semaglutide explains that GI effects are common, particularly at the start of treatment or after a dose increase, and usually ease within days to two weeks.

If symptoms feel severe or persist well beyond that window, contact your prescriber. Serious signs (for instance, sharp stomach pain that spreads to the back, which can indicate pancreatitis) need urgent medical attention. Report unexpected reactions through the MHRA Yellow Card scheme as well. For detailed guidance on what to expect week by week, the timeline for Wegovy's first dose is worth reading alongside this page.

When does the first dose start to matter for weight loss?

Clinically, the 0.25 mg period is not where trials measured their headline results. The STEP 1 study, which ran for 68 weeks and tested 2.4 mg semaglutide against placebo, found an average weight reduction of around 15%, but participants spent only four weeks at 0.25 mg before moving up. The cumulative effect of successive dose increases is where the numbers come from. Whether the lowest dose produces any measurable loss on its own varies considerably between individuals.

A useful comparison: the dose at which Wegovy tends to produce the clearest results is generally 1.7 mg and above. That is not a reason to rush the titration (the gradual approach exists to protect tolerability) but it does explain why early impatience is so common and so understandable.

If you are currently weighing up the options for a weight-loss treatment that suits your circumstances, the dose schedule is one of several factors worth discussing with a prescriber. Cost is another practical consideration, and a realistic picture of what Wegovy costs in the UK can help with planning. The key point is that the first dose is the beginning of a months-long process, not a single intervention.

When to speak to a prescriber before or after starting

Wegovy is a prescription-only medicine, and the prescribing decision involves a full clinical picture, not just your BMI. The licensed threshold is a BMI of 30 or above, or 27 or above alongside a weight-related condition such as hypertension, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber also reviews your full medication list, any relevant history, and your expectations about the pace of change.

If you are already on treatment and the first few doses have left you uncertain whether things are moving in the right direction, that is exactly what aftercare is for. At nume, a real clinician reads every consultation, your answers go to a prescriber's review, not an automated queue. The full Wegovy overview covers eligibility, results and how the clinical process works in more detail. When you're ready to take the next step, speak to our prescribers through a free consultation.